Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


24. August 2020 | 06:58 CET

BioNTech, CureVac, Valeo Pharma - the license to print money

  • Covid-19
Photo credits: pixabay.com

Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because there is enormous pressure to act from all sides. The sooner vaccines or other products are available, the sooner it will be possible to return to normal everyday life. While two German pharmaceutical companies are investing a lot of money in researching a vaccine, a Canadian competitor is taking an equally exciting and less risky route.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


The springboard to Canada

Valeo Pharma is a Canadian pharmaceutical company specializing in the licensing, approval and distribution of drugs. Small and medium-sized biotech companies involved in research often have the problem of having to arrange for commercialization once the drug is finished. This is exactly where Valeo Pharma's strength is, because the company is not involved in research and focuses on sales with attractive margins. This eliminates the high costs and risks associated with research and allows management to focus on products that have already been successfully tested. First and foremost, the Canadian home market is the main sales market. Access to physicians is particularly important because they usually prescribe the drugs to patients.

The company already has eight different products in its portfolio and six more in the pipeline. Last week, Valeo Pharma announced that it will increase its equity by CAD 6.00 million as part of a financing deal. If demand is high, the consortium accompanying the measure may increase the volume to up to CAD 6.90 million. In times of the Corona pandemic, a well-filled bank account is helpful to be able to increase, train and equip the staff accordingly. As soon as a partner with a Covid-19 drug knocks on Valeo Pharma's door, the company can enter into negotiations stronger. Valeo Pharma's market capitalization on Friday was just CAD 70.3 million and has corresponding potential due to this comparatively low base.

Research is progressing

BioNTech has already been keeping investors busy for several months. Since the company has joined forces with Pfizer to develop a vaccine against Covid-19, the share price has increased significantly. The company is now valued at more than USD 17.3 billion on the stock exchange. In the past, the experts focused on individual cancer therapies and are now leading the field internationally in the fight against the Corona Pandemic together with several other teams of experts.

In a test involving 30,000 patients, 11,000 people have already received a dose of a drug with a high chance of success. The expectations are already high that a vaccine will be available from BioNTech in the foreseeable future. Nobody can estimate how much potential the stock still has in the short term and what valuation level can be maintained.

Highflyer with chances of success

CureVac is a newcomer to the stock market and already has a market capitalisation of almost USD 12 billion. The German company also belongs to the global elite in research and received financial support from the German government in the race against the pandemic. The EU is already negotiating with CureVac on the possible availability of 225 million vaccine doses. Against this background, high expectations are now included in the company valuation.

The coming days, weeks and months will be exciting. Supplying several billion people with appropriate vaccine doses will be a gigantic task for the industry. In addition, the distribution of vaccine doses is of great economic and political importance. It is therefore not surprising that the company's shares are currently trading heavily.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. February 2021 | 08:15 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown

  • Covid-19

If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.

Read

21. December 2020 | 07:50 CET | by Stefan Feulner

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.

Read

02. November 2020 | 09:07 CET | by Stefan Feulner

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!

Read